Dosing and Modifications

Once-daily oral dosing with TALZENNA1
Dosing with TALZENNA (talazoparib). One dose. One time a day with or without food
  • The recommended starting dose of TALZENNA is 1 mg taken orally once daily, with or without food1
  • The 0.25 mg capsule is available for dose reduction1
  • Patients should be treated until disease progression or unacceptable toxicity occurs1
  • The capsules should be swallowed whole and must not be opened or dissolved1
  • If the patient vomits or misses a dose, an additional dose should not be taken. The next prescribed dose should be taken at the usual time1
Dose modifications
To manage adverse reactions, consider interruption of treatment or dose reduction based on severity and clinical presentation. Treatment with TALZENNA should be discontinued if more than 3 dose reductions are required.1
Dose Reduction Levels for Adverse Reactions1
Dose reduction levels for adverse reactions
Dose modification and adverse event management
Monitor complete blood counts monthly and as clinically indicated.1
Recommended dose modifications and management for adverse reactions.
Dose modifications for patients with renal impairment
  • For patients with moderate renal impairment (CLcr 30-59 mL/min), the recommended dose of TALZENNA is 0.75 mg once daily1
Dose modifications for use with P-glycoprotein (P-gp) inhibitors
  • Reduce the TALZENNA dose to 0.75 mg once daily when coadministered with certain P-gp inhibitors
  • When the P-gp inhibitor is discontinued, increase the TALZENNA dose (after 3-5 half-lives of the P-gp inhibitor) to the dose used prior to the initiation of the P-gp inhibitor1
REFERENCE
  1. TALZENNA [prescribing information]. New York, NY: Pfizer Inc; 2018.